ClinicalTrials.Veeva

Menu

Aurora Test for ART Donor Patients (AURORA-Donor)

F

Fertiga

Status

Enrolling

Conditions

Infertility

Treatments

Other: AURORA-Donor

Study type

Observational

Funder types

Industry
Other

Identifiers

NCT06280677
2023.Aurora-Donor

Details and patient eligibility

About

This is a randomized observational study. The main aim is to determine potential oocyte competence predictive mRNA expression profiles in the cumulus cells isolated form individual oocytes. In 2 patient cohorts: 1)GnRH Antagonist & hr-FSH with GnRH Agonist trigger, 2) Progesterone & hr-FSH with GnRH Agonist trigger.

Enrollment

160 estimated patients

Sex

Female

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria Donor:

  • Patients are 18 to 35 years old
  • BMI between 17-30
  • Regular menstrual cycles
  • AFC > 8
  • Patient profile in compliance with SEF (Sociedad Española de Fertilidad) directives for egg donation (medical, psychological and genetic screening, informed consent)
  • Patients' stimulation: GnRH Antagonist & hr-FSH with GnRH Agonist trigger or Progesterone & hr-FSH with GnRH Agonist trigger
  • Patients agree that the oocytes will be denuded for cumulus testing and provide written informed consent for participation to the study

Exclusion Criteria Donor:

  • BMI < 17 or > 30
  • Extreme irregular menstrual cycles (<20 days or >40 days)
  • AFC < 8
  • <8 MII on previous egg retrieval
  • Women with history of poor oocyte maturation or known maturation defect or unexplained failure in previous treatments
  • Patients that fail to comply with SEF (Sociedad Española de Fertilidad) directives for egg donation (medical, psychological and genetic screening, informed consent)

Inclusion Criteria Recipient:

  • Patients applying for ART egg donation with fresh/frozen sperm from the partner or frozen donor sperm. With eSB-FET in modified natural cycle or an HRT cycle.
  • Patients are from 18 to 50 years old.
  • Patients will be treated by ICSI (intracytoplasmic sperm injection) and eSB-FET (elective Single Blastocyst Frozen Embryo Transfer)
  • Recipient patients agree that the donors' oocytes will be denuded for cumulus testing and provide written informed consent for participation to the study

Exclusion Criteria for oocyte Recipients

  • Patient included in any other prospective study.
  • BMI < 17 or > 35
  • Severe uterine factor: Multiple myomectomy, multiple fibroids, major uterine malformation (unicorn, septum), Asherman Sd, severe adenomyosis
  • Repeated Implantation Failure or Repeated Pregnancy Loss after euploid Single Blastocyst Transfer
  • Severe male factor: Abnormal Caryotype or FISH, severe OAT / Cripto-Azoospermia, DNA Fragmentation >50% after medical treatment
  • TESE / TESA (testicular sperm extraction/aspiration)

Trial design

160 participants in 2 patient groups

GnRH Antagonist & hr-FSH
Description:
Patients stimulated with GnRH Antagonist \& hr-FSH with GnRH Agonist trigger
Treatment:
Other: AURORA-Donor
Progesterone & hr-FSH
Description:
Patients stimulated with Progesterone \& hr-FSH with GnRH Agonist trigger
Treatment:
Other: AURORA-Donor

Trial contacts and locations

1

Loading...

Central trial contact

Tom Adriaenssens, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems